Cargando…

Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda

BACKGROUND: People living in malaria endemic areas acquire protection from severe malaria quickly, but protection from clinical disease and control of parasitaemia is acquired only after many years of repeated infections. Antibodies play a central role in protection from clinical disease; however, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ssewanyana, Isaac, Arinaitwe, Emmanuel, Nankabirwa, Joaniter I., Yeka, Adoke, Sullivan, Richard, Kamya, Moses R., Rosenthal, Philip J., Dorsey, Grant, Mayanja-Kizza, Harriet, Drakeley, Chris, Greenhouse, Bryan, Tetteh, Kevin K. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301436/
https://www.ncbi.nlm.nih.gov/pubmed/28183299
http://dx.doi.org/10.1186/s12936-017-1721-3
_version_ 1782506365193814016
author Ssewanyana, Isaac
Arinaitwe, Emmanuel
Nankabirwa, Joaniter I.
Yeka, Adoke
Sullivan, Richard
Kamya, Moses R.
Rosenthal, Philip J.
Dorsey, Grant
Mayanja-Kizza, Harriet
Drakeley, Chris
Greenhouse, Bryan
Tetteh, Kevin K. A.
author_facet Ssewanyana, Isaac
Arinaitwe, Emmanuel
Nankabirwa, Joaniter I.
Yeka, Adoke
Sullivan, Richard
Kamya, Moses R.
Rosenthal, Philip J.
Dorsey, Grant
Mayanja-Kizza, Harriet
Drakeley, Chris
Greenhouse, Bryan
Tetteh, Kevin K. A.
author_sort Ssewanyana, Isaac
collection PubMed
description BACKGROUND: People living in malaria endemic areas acquire protection from severe malaria quickly, but protection from clinical disease and control of parasitaemia is acquired only after many years of repeated infections. Antibodies play a central role in protection from clinical disease; however, protective antibodies are slow to develop. This study sought to investigate the influence of Plasmodium falciparum exposure on the acquisition of high-avidity antibodies to P. falciparum antigens, which may be associated with protection. METHODS: Cross-sectional surveys were performed in children and adults at three sites in Uganda with varied P. falciparum transmission intensity (entomological inoculation rates; 3.8, 26.6, and 125 infectious bites per person per year). Sandwich ELISA was used to measure antibody responses to two P. falciparum merozoite surface antigens: merozoite surface protein 1-19 (MSP1-19) and apical membrane antigen 1 (AMA1). In individuals with detectable antibody levels, guanidine hydrochloride (GuHCl) was added to measure the relative avidity of antibody responses by ELISA. RESULTS: Within a site, there were no significant differences in median antibody levels between the three age groups. Between sites, median antibody levels were generally higher in the higher transmission sites, with differences more apparent for AMA-1 and in ≥5 year group. Similarly, median avidity index (proportion of high avidity antibodies) showed no significant increase with increasing age but was significantly lower at sites of higher transmission amongst participants ≥5 years of age. Using 5 M GuHCl, the median avidity indices in the ≥5 year group at the highest and lowest transmission sites were 19.9 and 26.8, respectively (p = 0.0002) for MSP1-19 and 12.2 and 17.2 (p = 0.0007) for AMA1. CONCLUSION: Avidity to two different P. falciparum antigens was lower in areas of high transmission intensity compared to areas with lower transmission. Appreciation of the mechanisms behind these findings as well as their clinical consequences will require additional investigation, ideally utilizing longitudinal data and investigation of a broader array of responses.
format Online
Article
Text
id pubmed-5301436
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53014362017-02-15 Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda Ssewanyana, Isaac Arinaitwe, Emmanuel Nankabirwa, Joaniter I. Yeka, Adoke Sullivan, Richard Kamya, Moses R. Rosenthal, Philip J. Dorsey, Grant Mayanja-Kizza, Harriet Drakeley, Chris Greenhouse, Bryan Tetteh, Kevin K. A. Malar J Research BACKGROUND: People living in malaria endemic areas acquire protection from severe malaria quickly, but protection from clinical disease and control of parasitaemia is acquired only after many years of repeated infections. Antibodies play a central role in protection from clinical disease; however, protective antibodies are slow to develop. This study sought to investigate the influence of Plasmodium falciparum exposure on the acquisition of high-avidity antibodies to P. falciparum antigens, which may be associated with protection. METHODS: Cross-sectional surveys were performed in children and adults at three sites in Uganda with varied P. falciparum transmission intensity (entomological inoculation rates; 3.8, 26.6, and 125 infectious bites per person per year). Sandwich ELISA was used to measure antibody responses to two P. falciparum merozoite surface antigens: merozoite surface protein 1-19 (MSP1-19) and apical membrane antigen 1 (AMA1). In individuals with detectable antibody levels, guanidine hydrochloride (GuHCl) was added to measure the relative avidity of antibody responses by ELISA. RESULTS: Within a site, there were no significant differences in median antibody levels between the three age groups. Between sites, median antibody levels were generally higher in the higher transmission sites, with differences more apparent for AMA-1 and in ≥5 year group. Similarly, median avidity index (proportion of high avidity antibodies) showed no significant increase with increasing age but was significantly lower at sites of higher transmission amongst participants ≥5 years of age. Using 5 M GuHCl, the median avidity indices in the ≥5 year group at the highest and lowest transmission sites were 19.9 and 26.8, respectively (p = 0.0002) for MSP1-19 and 12.2 and 17.2 (p = 0.0007) for AMA1. CONCLUSION: Avidity to two different P. falciparum antigens was lower in areas of high transmission intensity compared to areas with lower transmission. Appreciation of the mechanisms behind these findings as well as their clinical consequences will require additional investigation, ideally utilizing longitudinal data and investigation of a broader array of responses. BioMed Central 2017-02-10 /pmc/articles/PMC5301436/ /pubmed/28183299 http://dx.doi.org/10.1186/s12936-017-1721-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ssewanyana, Isaac
Arinaitwe, Emmanuel
Nankabirwa, Joaniter I.
Yeka, Adoke
Sullivan, Richard
Kamya, Moses R.
Rosenthal, Philip J.
Dorsey, Grant
Mayanja-Kizza, Harriet
Drakeley, Chris
Greenhouse, Bryan
Tetteh, Kevin K. A.
Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title_full Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title_fullStr Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title_full_unstemmed Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title_short Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda
title_sort avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in uganda
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301436/
https://www.ncbi.nlm.nih.gov/pubmed/28183299
http://dx.doi.org/10.1186/s12936-017-1721-3
work_keys_str_mv AT ssewanyanaisaac avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT arinaitweemmanuel avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT nankabirwajoaniteri avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT yekaadoke avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT sullivanrichard avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT kamyamosesr avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT rosenthalphilipj avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT dorseygrant avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT mayanjakizzaharriet avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT drakeleychris avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT greenhousebryan avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda
AT tettehkevinka avidityofantimalarialantibodiesinverselyrelatedtotransmissionintensityatthreesitesinuganda